Onconic Therapeutics Inc.
Onconic Therapeutics Inc.
Explore linked clinical trials.9 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis | Maintenance of Healed Erosive Gastroesophageal Reflux Disease (ERD) | Not yet recruiting | Phase 3 | 2026-07-28 | NCT07732075 | |
| Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male Participants | Healthy Volunteers | Not yet recruiting | Phase 1 | 2026-05-06 | NCT07570186 | |
| Study to Assess the Safety, Tolerability of JPI-547 in Combination With Modified FOLFIRINOX or Gemcitabine-nab-paclitaxel in Patients With Locally Advanced and Metastatic Pancreatic Cancer | pancreatic ductal adenocarcinoma | Recruiting | Phase 1 / Phase 2 | 2026-04-13 | NCT05257993 | |
| To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder | Not yet recruiting | Phase 2 | 2026-01-27 | NCT07370818 | |
| To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Not yet recruiting | Phase 1 / Phase 2 | 2026-01-23 | NCT07364422 | |
| to Evaluate the Safety and the Pharmacokinetic and Pharmacodynamic Interactions Between JP-1366 and Clopidogrel, Aspirin, Atorvastatin and Apixaban | Drug Drug Interaction (DDI) | Recruiting | Phase 1 | 2025-12-04 | NCT07265466 | |
| Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease | Deglutition Disorders, Digestive System Diseases, Non-Erosive Reflux Disease, digestive system disorder, dyskinesia of esophagus, esophageal disorder, gastroesophageal reflux disease | Not yet recruiting | Phase 3 | 2025-09-08 | NCT07160790 | |
| First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrial carcinoma, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Recruiting | Phase 2 | 2025-04-03 | NCT06502743 | |
| Study to Evaluate the Efficacy and Safety of JP-1366 in the Prevention of NSAIDs-Induced Peptic Ulcers | Digestive System Diseases, digestive system disorder, duodenal disorder, intestinal disorder, peptic ulcer disease, stomach disorder | Recruiting | Phase 3 | 2024-11-01 | NCT06439563 |